摘要
幽门螺杆菌(Hp)感染是胃癌的重要风险因素,也是多种消化系统疾病的主要病因之一。本文基于国内外文献,从Hp感染的致病过程、Hp感染胃黏膜的免疫过程、Hp感染的诊治等角度梳理了Hp免疫感染过程与临床诊治。结果发现机制研究中CD4^(+)T细胞亚群在Hp感染中的关键作用逐渐受到国内外研究的重视。在临床诊治方面,含铋剂四联疗法被学术界反复验证并得到认同;钾离子竞争性酸阻滞剂(P-CAB)作为根除治疗的研究热点,未来有可能替代质子泵抑制剂(PPI)成为新的一线治疗药物。
Helicobacter pylori(Hp)infection is an important risk factor for gastric cancer and one of the the primary causes of multiple digestive system diseases.Based on the literature at home and abroad,this article reviews the process of Hp immune infection and clinical diagnosis and treatment from the perspectives of the pathogenic process of Hp infection,the immune process of Hp infected gastric mucosa,and the diagnosis and treatment of Hp infection.The results showed that the key role of CD4^(+)T cell subsets in Hp infection has garnered increasing attention in mechanistic research both domestically and internationally.In terms of clinical diagnosis and treatment,bismuth-containing quadruple therapy has been repeatedly validated and recognized by the academic community;as a research hotspot of eradication therapy,potassium-competitive acid blocker(P-CAB)may replace proton pump inhibitor(PPI)as a new first-line treatment drug in the future.
作者
任丽江
杨胜男
董丽丽
姚文
王萍
REN Lijiang;YANG Shengnan;DONG Lili;YAO Wen;WANG Ping(Beijing University of Chinese Medicine,Beijing 100029;People's Hospital of Rizhao,Rizhao 276800;Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing 100091,China)
出处
《临床医学研究与实践》
2025年第36期191-194,共4页
Clinical Research and Practice
基金
中国中医科学院基本科研业务费自主选题项目。
关键词
幽门螺杆菌
胃癌前病变
免疫过程
Helicobacter pylori
gastric precancerous lesion
immune process
